8-K: Corvus Reports Q4/FY25 Results, Advances Soquelitinib Trials

Corvus Pharmaceuticals announced its fourth quarter and full year 2025 financial results, alongside positive clinical data for soquelitinib in atopic dermatitis and progress in its PTCL and other immune disease programs, bolstered by a recent $189 million financing.

Summary

• Reported financial results for the fourth quarter and full year ended December 31, 2025.
• Announced positive safety and efficacy data from cohort 4 of the soquelitinib Phase 1 atopic dermatitis trial, including in patients who have received prior systemic therapy.
• Initiated a Phase 2 randomized placebo-controlled atopic dermatitis clinical trial for soquelitinib in Q1 2026, targeting approximately 200 patients.
• Completed a public offering on January 23, 2026, raising net proceeds of $189.4 million, extending the cash runway into the second quarter of 2028.
• Continued enrollment in the registrational Phase 3 clinical trial of soquelitinib in patients with relapsed/refractory Peripheral T Cell Lymphoma (PTCL).
• Angel Pharmaceuticals, Corvus's partner in China, is enrolling a Phase 1b/2 clinical trial evaluating soquelitinib in moderate-to-severe atopic dermatitis, with initial results anticipated late this year.
• Patient enrollment continues in the Autoimmune Lymphoproliferative Syndrome (ALPS) Phase 2 clinical trial, conducted under a collaboration with NIAID.
• Plans to initiate two additional Phase 2 trials for soquelitinib in asthma and hidradenitis suppurativa later this year.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, driven by compelling early clinical efficacy and safety data for soquelitinib in atopic dermatitis and PTCL, coupled with a substantial financing that significantly de-risks operations and enables pipeline advancement.

Positives

• Soquelitinib Phase 1 atopic dermatitis trial (cohort 4) demonstrated strong efficacy: 75% of patients achieved EASI 75, 25% achieved EASI 90, and 33% achieved IGA 0/1, significantly outperforming the placebo group (20%, 0%, and 0% respectively).
• Positive efficacy results were achieved in atopic dermatitis patients who had received prior systemic therapy, including those resistant to approved therapies like dupilumab and JAK inhibitors.
• New long-term data for cohort 3 showed maintenance or improvement in EASI out to three months beyond the treatment period, associated with an increase of circulating Treg cells.
• Soquelitinib exhibited a positive safety profile with no new safety signals, severe or serious adverse events, or significant lab abnormalities across over 150 patients and 14,000 patient treatment days.
• No patient has required dose modification or treatment-related drug discontinuation in any soquelitinib clinical trials.
• A public offering completed on January 23, 2026, raised approximately $189.4 million in net proceeds.
• The company's cash runway has been extended into the second quarter of 2028.
• Progress continues in the registrational Phase 3 PTCL trial, and a Phase 2 atopic dermatitis trial has been initiated.
• Soquelitinib has received Orphan Drug Designation and Fast Track designation from the FDA for the treatment of T cell lymphoma and relapsed/refractory PTCL, respectively.
• Final data from the Phase 1/1b PTCL trial showed median progression-free survival of 6.2 months and median overall survival of 28.1 months in the 200 mg BID cohort, comparing favorably to other therapies.
• No viral reactivation or associated illness was observed in lymphoma patients with Epstein Barr Virus (EBV) at baseline who received soquelitinib.

Negatives

• Net loss for the three months ended December 31, 2025, increased slightly to $12.3 million from $12.1 million for the same period in 2024.
• Research and development expenses significantly increased to $9.9 million for Q4 2025 (from $6.0 million in Q4 2024) and $33.7 million for the full year 2025 (from $19.4 million in FY 2024), primarily due to higher clinical trial and manufacturing costs, and personnel-related costs.

Risks

• The company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of product candidates.
• The accuracy of the company's estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials.
• The results of preclinical studies and interim data from clinical trials not being predictive of future results.
• The company's ability to enroll sufficient numbers of patients in its clinical trials.
• The unpredictability of the regulatory process.
• Regulatory developments in the United States and foreign countries.
• The costs of clinical trials may exceed expectations.
• The company's ability to accurately estimate the cash on hand providing funding into the second quarter of 2028 and its ability to raise additional capital.

Future Outlook

The company anticipates continued enrollment in its registrational Phase 3 PTCL trial and its recently initiated Phase 2 atopic dermatitis trial. Additional data from the Phase 1 atopic dermatitis trial will be reported at the Society of Investigative Dermatology (SID) meeting. Plans are advancing to initiate two additional Phase 2 trials in asthma and hidradenitis suppurativa later this year. Initial results from Angel Pharmaceuticals' Phase 1b/2 atopic dermatitis trial are expected late this year. The recent financing is expected to fund operations into the second quarter of 2028.

Management Comments

• Richard A. Miller, M.D., co-founder, president and chief executive officer, stated, "We believe the recent cohort 4 data from our Phase 1 atopic dermatitis trial demonstrate that soquelitinib has the potential to be an important new medicine for a broad range of patients with atopic dermatitis and other immune diseases."
• Dr. Miller also highlighted, "The data also highlight the unique mechanism of action with ITK inhibition, regulating multiple T cell functional pathways that leads to an immune system resetting that may be effective in treating many diseases."
• Regarding near-term focus, Dr. Miller commented, "Our near-term focus is the ongoing enrollment of our registration Phase 3 peripheral T cell lymphoma (PTCL) trial, getting off to a strong start with our recently initiated Phase 2 atopic dermatitis trial, and reporting additional data from the Phase 1 trial at the Society of Investigative Dermatology (SID) meeting."
• Dr. Miller added, "We are also advancing our plans to initiate two additional Phase 2 trials in asthma and hidradenitis suppurativa later this year."
• On financing, Dr. Miller noted, "Our recent financing will enable us to advance all of these programs through key data readouts, providing significant opportunity to further demonstrate the value of soquelitinibs pipeline-in-a-product potential."

Industry Context

StockSavvy.ai notes that the positive Phase 1 data for soquelitinib in atopic dermatitis, particularly its efficacy in patients resistant to approved therapies like dupilumab and JAK inhibitors, positions it as a potentially significant new entrant in a competitive but high-need market. The unique ITK inhibition mechanism, leading to immune system resetting, could differentiate it from existing treatments. The progress in PTCL, where there are no FDA fully approved agents based on randomized trials and existing therapies offer poor outcomes (median PFS 3-4 months, OS 6-12 months), highlights soquelitinib's potential to address a critical unmet medical need.

Comparison to Industry Standards

• For atopic dermatitis, soquelitinib's 75% EASI 75 and 25% EASI 90 in cohort 4 compare favorably to some existing therapies. Leading biologics like dupilumab typically show EASI 75 rates around 35-40% at 16 weeks in moderate-to-severe patients in pivotal trials. JAK inhibitors such as abrocitinib and upadacitinib have demonstrated EASI 75 rates ranging from 40-60% at 12-16 weeks depending on dose. Soquelitinib's early data suggests a competitive profile, especially given its safety and efficacy in treatment-resistant patients.
• For relapsed/refractory PTCL, soquelitinib's median progression-free survival of 6.2 months and median overall survival of 28.1 months (from the 200 mg BID cohort of the Phase 1/1b trial) compare favorably to current physician's choice chemotherapies like belinostat or pralatrexate, which typically yield median PFS in the 3-4 month range and median OS of 6-12 months. This suggests a significant improvement over existing options for a disease with high unmet need.

Related Party Transactions

• Corvus holds a 49.7% equity stake in Angel Pharmaceuticals (excluding 7% reserved for Angel's employee stock ownership plan).
• Corvus has designated three individuals on Angel Pharmaceuticals' five-person Board of Directors.
• Angel Pharmaceuticals licensed the rights to develop and commercialize Corvus's three clinical-stage candidates (soquelitinib, ciforadenant, and mupadolimab) in greater China.
• Angel Pharmaceuticals also obtained global rights to Corvus's BTK inhibitor preclinical programs.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, extended cash runway, and pipeline progress, potentially increasing company valuation and reducing dilution risk in the near term.
• Patients: Potential for new, effective treatment options for atopic dermatitis, PTCL, ALPS, asthma, and hidradenitis suppurativa, especially for those resistant to current therapies, offering improved quality of life and survival outcomes.
• Employees: Increased job security and potential for growth as clinical programs advance and the company's financial position strengthens.
• Creditors: Improved financial stability due to a significant capital raise, enhancing the company's ability to meet its obligations.
• Partners (Angel Pharmaceuticals, NIAID): Continued collaboration and potential for shared success in developing soquelitinib and other candidates, reinforcing strategic alliances.

Next Steps

• Continue ongoing enrollment of the registrational Phase 3 PTCL trial.
• Continue ongoing enrollment of the Phase 2 atopic dermatitis trial.
• Report additional data from the Phase 1 atopic dermatitis trial at the Society of Investigative Dermatology (SID) meeting.
• Initiate two additional Phase 2 trials in asthma and hidradenitis suppurativa later this year.
• Anticipate results from initial cohorts of Angel Pharmaceuticals' Phase 1b/2 atopic dermatitis trial late this year.
• Host a conference call and webcast on March 12, 2026, at 4:30 p.m. ET / 1:30 p.m. PT.

Key Dates

Recommendation

The filing presents highly encouraging clinical data for soquelitinib in atopic dermatitis, demonstrating strong efficacy and a clean safety profile, even in patients who failed prior systemic therapies. This positions soquelitinib as a potential best-in-class or first-in-class therapy for a significant market. Furthermore, the successful $189.4 million capital raise substantially strengthens the company's financial position, extending its cash runway into Q2 2028, which de-risks operations and provides ample funding for multiple ongoing and planned Phase 2 and Phase 3 trials. The progress in the registrational PTCL trial and the broad "pipeline-in-a-product" potential of soquelitinib across various immune diseases and cancer indications suggest significant long-term value creation. The financial results, while showing increased R&D expenses, are expected for a clinical-stage company advancing multiple programs, and the net loss reduction year-over-year (excluding warrant liability impact) is also positive.

Keywords

Soquelitinib, Atopic Dermatitis, Peripheral T Cell Lymphoma, PTCL, ITK inhibitor, Biopharmaceutical, Clinical Trial, Immunotherapy, Autoimmune diseases, Cancer, Orphan Drug Designation, Fast Track designation, NIAID, Angel Pharmaceuticals, Cash runway, Public offering